Evercore ISI analyst Josh Schimmer is bullish on biotech.
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
Big gains could be ahead for investors willing to stick with the stock, according to one firm.
My three top predictions for the next six months.
The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.
©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.